Related to CMO Market Gets Back on the Fast Track

• Genzyme Plant Shutdown Could Mean up to $300M in Lost Sales
  Sales of drugs for Fabry, Gaucher’s, and Pompe diseases will take a hit.
  
• Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s
  Shortage could lead to more choices for patients sooner than expected.
  
• Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise
  If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.
  
• Refocusing on Therapeutic Protein Production in Plants
  Recent contamination issues with Genzyme’s CHO-cell manufacturing has highlighted the advantages of plant-based techniques.
  
• Puerto Rico Blindsides Manufacturers
  Industry is lobbying against new tax rules, expected to raise $6 billion over six years.
  
• Will Antibody Biosimilars See the Light of Day?
  Firms copying innovator therapeutic mAbs face manufacturing and regulatory challenges.
  
• CMOs Seek Growth Beyond Traditional Contract Manufacturing
  Providers are seeking out strategic partnerships and developing niche expertise.
  
• Surveys Point to Biopharmas Following the Money by Outsourcing More
  CROs are playing a growing role in R&D, and companies are also offshoring clinical trials.
  
• Biopharma Job Outlook Bleak through Mid-Decade
  Restructuring, outsourcing, and patent expirations have combined to create a tumultuous job market.
  
• CMOs Capitalizing on Experience to Develop Their Own Therapeutics
  A few pioneering contract manufacturing organizations are testing the drug development waters.
  
• Not Quite 1918, but Flu Still Deadly
  Authorities and manufacturers look ahead to new vaccines and immunization efforts while scrambling to deal with spot shortages.
  
• High-Tech Companies Buy Into Biomanufacturing
  Samsung and Fujifilm believe such high-investment diversification will help business.